DNA methylation signatures from tissue and cell-free DNA in alpha-1 antitrypsin deficiency mirror clinical pathologies providing a potential non-invasive tool to monitor liver disease progression

Alpha-1 antitrypsin deficiency (AATD) is a serpinopathy in which mutations in the SERPINA1 gene cause misfolding of alpha-1 antitrypsin (Z-AAT), leading to hepatic protein accumulation, proteotoxic stress, inflammation, fibrosis, and an increased risk of hepatocellular carcinoma. Despite a uniform genetic mutation in most affected individuals, liver disease severity varies, reflecting contributions from environmental exposures and epigenetic heterogeneity (e.g. DNA methylation). As RNA-interference therapy has emerged as a promising treatment, understanding how epigenetic variation relates to the clinical and histopathologic features of AATD may provide insight into disease heterogeneity, progression, and therapeutic response. We analyzed a longitudinal cohort of ZZ-genotype AATD patients with paired liver biopsies, plasma cell-free DNA (cfDNA), and clinical data collected at baseline and 3-y follow-up. Genome-wide DNA methylation profiling of liver tissue identified 15 CpG clusters associated with liver disease severity, immune pathways, and clinical measures including METAVIR fibrosis score and γ-glutamyltransferase. Parallel methylation profiling of matched plasma-derived cfDNA identified eight analogous CpG clusters enriched for similar biological pathways and associated with clinical parameters. Integration of tissue and cfDNA datasets revealed fifty-one shared CpGs representing disease-associated methylation signatures, including loci such as ZFP57 that tracks with portal inflammation. We also identified a DNA methylation signature associated with fibrosis progression based on changes in METAVIR score. These findings demonstrate that liver- and cfDNA-derived DNA methylation signatures robustly stratify AATD patients by relevant measures of liver injury and fibrosis, supporting their potential as non-invasive biomarkers for diagnosis, prognosis, and monitoring responses to emerging therapies.

Authors

Institutions

Publication Details

Journal
Epigenetics
Published
2026-11-20
DOI
https://doi.org/10.1080/15592294.2026.2760044
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

DNA methylation signatures from tissue and cell-free DNA in alpha-1 antitrypsin deficiency mirror clinical pathologies providing a potential non-invasive tool to monitor liver disease progression

Ryan T. Wagner, Virginia Clark, George W. Marek, Keith D. Robertson et al.
1 links
Epigenetics
Epigenetics and DNA Methylation
article

DNA methylation signatures from tissue and cell-free DNA in alpha-1 antitrypsin deficiency mirror clinical pathologies providing a potential non-invasive tool to monitor liver disease progression

Ryan T. Wagner, Virginia Clark, George W. Marek, Keith D. Robertson, Ryan A. Hlady, Mark Brantly, Liguo Wang, Chen Liu, Xia Zhao
article en

Abstract

Alpha-1 antitrypsin deficiency (AATD) is a serpinopathy in which mutations in the SERPINA1 gene cause misfolding of alpha-1 antitrypsin (Z-AAT), leading to hepatic protein accumulation, proteotoxic stress, inflammation, fibrosis, and an increased risk of hepatocellular carcinoma. Despite a uniform genetic mutation in most affected individuals, liver disease severity varies, reflecting contributions from environmental exposures and epigenetic heterogeneity (e.g. DNA methylation). As RNA-interference therapy has emerged as a promising treatment, understanding how epigenetic variation relates to the clinical and histopathologic features of AATD may provide insight into disease heterogeneity, progression, and therapeutic response. We analyzed a longitudinal cohort of ZZ-genotype AATD patients with paired liver biopsies, plasma cell-free DNA (cfDNA), and clinical data collected at baseline and 3-y follow-up. Genome-wide DNA methylation profiling of liver tissue identified 15 CpG clusters associated with liver disease severity, immune pathways, and clinical measures including METAVIR fibrosis score and γ-glutamyltransferase. Parallel methylation profiling of matched plasma-derived cfDNA identified eight analogous CpG clusters enriched for similar biological pathways and associated with clinical parameters. Integration of tissue and cfDNA datasets revealed fifty-one shared CpGs representing disease-associated methylation signatures, including loci such as ZFP57 that tracks with portal inflammation. We also identified a DNA methylation signature associated with fibrosis progression based on changes in METAVIR score. These findings demonstrate that liver- and cfDNA-derived DNA methylation signatures robustly stratify AATD patients by relevant measures of liver injury and fibrosis, supporting their potential as non-invasive biomarkers for diagnosis, prognosis, and monitoring responses to emerging therapies.

EpigeneticsVol. 21(1)
Mayo Clinic (US), University of Florida Health (US), Yale University (US), University of Florida (US)
American Liver Foundation
Good health and well-being
Epigenetics and DNA Methylation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon